Keywords
Abstract
The purpose of this review is to provide an update on the epidemiology, risk factors, and management of cardiac arrhythmias in oncological patients, in the context of the new European Society of Cardiology 2022 guidelines on cardio-oncology. It has been found that some chemotherapeutics have pro arrhythmic activity, leading to the induction of both atrial and ventricular arrhythmias. Recent studies have reported on the cardiotoxic activity of promising therapies such as BRAF and MEK inhibitors, as well as CAR-T therapy. Risk factors for arrhythmias in oncological patients overlap with those of cardiovascular diseases,
but certain groups of anticancer drugs increase the risk of cardiotoxicity. It is crucial to be aware of the risks associated with oncological treatment and to know how to act in case of cardiotoxicity.